BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23846486)

  • 1. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
    Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
    Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
    Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
    Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
    Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
    Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
    Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
    J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.
    Chow HH; Cai Y; Hakim IA; Crowell JA; Shahi F; Brooks CA; Dorr RT; Hara Y; Alberts DS
    Clin Cancer Res; 2003 Aug; 9(9):3312-9. PubMed ID: 12960117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E).
    Fu H; He J; Mei F; Zhang Q; Hara Y; Ryota S; Lubet RA; Chen R; Chen DR; You M
    Cancer Prev Res (Phila); 2009 Jun; 2(6):531-7. PubMed ID: 19470785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
    Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
    Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.
    Gee JR; Saltzstein DR; Kim K; Kolesar J; Huang W; Havighurst TC; Wollmer BW; Stublaski J; Downs T; Mukhtar H; House MG; Parnes HL; Bailey HH
    Cancer Prev Res (Phila); 2017 May; 10(5):298-307. PubMed ID: 28325826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.
    Nguyen MM; Ahmann FR; Nagle RB; Hsu CH; Tangrea JA; Parnes HL; Sokoloff MH; Gretzer MB; Chow HH
    Cancer Prev Res (Phila); 2012 Feb; 5(2):290-8. PubMed ID: 22044694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions.
    Ahn WS; Yoo J; Huh SW; Kim CK; Lee JM; Namkoong SE; Bae SM; Lee IP
    Eur J Cancer Prev; 2003 Oct; 12(5):383-90. PubMed ID: 14512803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of human glutathione s-transferases by polyphenon e intervention.
    Chow HH; Hakim IA; Vining DR; Crowell JA; Tome ME; Ranger-Moore J; Cordova CA; Mikhael DM; Briehl MM; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1662-6. PubMed ID: 17684143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
    Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
    J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.
    Irving PM; Iqbal T; Nwokolo C; Subramanian S; Bloom S; Prasad N; Hart A; Murray C; Lindsay JO; Taylor A; Barron R; Wright S
    Inflamm Bowel Dis; 2018 Mar; 24(4):714-724. PubMed ID: 29538683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.